Given the significant functional impairment and the phenotypic profile suggestive of a CGRP-related mechanism, treatment with erenumab, a CGRP receptor antagonist, was initiated based on previous reports of its efficacy in similar migraine-like NDPH phenotypes. Here, CALCA is linked to migraine disorder.